Vanguard Global Advisers
TPST icon

Vanguard Global Advisers’s Tempest Therapeutics TPST Stock Holding History

Vanguard Global Advisers’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-168
Closed -$276 – 3733
2026
Q1 		$276 Buy
+168
New +$405 ﹤0.01% 3668

Other funds holding TPST

SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Global Advisers's TPST Position: Q2 2026 in Review

Vanguard Global Advisers sold out of Tempest Therapeutics (TPST) in Q2 2026, closing a stake of 168 shares — an estimated $276 sold.

Vanguard Global Advisers first reported a position in TPST in Q1 2026 and held it in 1 quarter. The position peaked at $276 in Q1 2026. 21 funds tracked by Wall St. Rank hold TPST as of Q2 2026.

  • Vanguard Global Advisers reported no remaining Tempest Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Vanguard Global Advisers sold 168 Tempest Therapeutics shares in Q2 2026, an estimated $276.
  • Vanguard Global Advisers first reported a position in Tempest Therapeutics in Q1 2026 and held it in 1 quarter.
  • Vanguard Global Advisers's Tempest Therapeutics position peaked at $276 in Q1 2026.
  • 21 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.